An Evaluation of the Tumor Microenvironment through CALR, IL1R1, IFNB1, and IFNG to Assess Prognosis and Immunotherapy Response in Bladder Cancer Patients
Authors:
- Liu LilongLLLiu Lilong
- Liu ZhenghaoLZLiu Zhenghao
- Fan LeiFLFan Lei
- Yao ZhipengYZYao Zhipeng
- Hu JunyiHJHu Junyi
- Hou YaxinHYHou Yaxin
- Li YangLYLi Yang
- Ding YuhongDYDing Yuhong
- Kuang YingchunKYKuang Yingchun
- Chen KeCKChen Ke
- Hao YiHYHao Yi
- Liu ZhengLZLiu Zheng
Preprint
Abstract
Immunogenic cell death (ICD) is a type of cell death sparking adaptive immune responses, can reshape the tumor microenvironment (TME). Exploring key ICD-related genes in bladder cancer (BLCA) could enhance personalized treatment. TCGA BLCA patients were divided into two ICD subtypes: ICD-high and ICD-low. High ICD expression linked to increased immune cell infiltration and longer survival, but with potentially suppressed immune function. The high ICD group responded better to PD1-targeted therapy. A risk-scoring model with four ICD-related genes (CALR, IL1R1, IFNB1, IFNG) was validated across TCGA, GEO datasets, and tissue samples, showing higher risk-score correlated with weaker anti-tumor immune function, more tumor-promoting elements, lower immunotherapy response rates, and shorter patient survival.This study connects ICD-related genes to BLCA prognosis and immune infiltration, offering a vital tool for personalized treatment guidance.Keywords
All Related Versions
- Published version: eLife, 13.
Funding Information
- National Natural Science Foundation of China (82303623)
- National Key Research and Development Project of China (2019YFA0905600)
- the China Postdoctoral Science Foundation (2023M731199)
- the Postdoctoral Innovation Research Post of Hubei Provincial Department of Human Resources and Social Security (331048)
This publication has 25 references indexed in Scilit:
- The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cellsCancer Cell, 2023
- Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)World Journal of Urology, 2023
- Cisplatin and Albumin-Based Gold–Cisplatin Nanoparticles Enhance Ablative Radiation Therapy–Induced Antitumor Immunity in Local and Distant Tumor MicroenvironmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancerSignal Transduction and Targeted Therapy, 2021
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyThe Lancet Oncology, 2021
- Intracellular aggregation of peptide-reprogrammed small molecule nanoassemblies enhances cancer chemotherapy and combinatorial immunotherapyActa Pharmaceutica Sinica B, 2021
- Cancer-associated fibroblasts in tumor microenvironment – Accomplices in tumor malignancyCellular Immunology, 2019
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2017
- Immunogenic cell death in cancer and infectious diseaseNature Reviews Immunology, 2016
- Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapyEuropean Journal of Immunology, 2014